GlaxoSmithKline's Votrient gets US panel nod for renal cancer
06 October 2009
Sue Sutter
Please Login to read the full article.
06 October 2009
Sue Sutter
GlaxoSmithKline's oral anti-angiogenic Votrient (pazopanib) won the overwhelming endorsement of the US
FDA's oncologic drugs advisory panel for treating advanced renal cell carcinoma. The agency's experts voted 10 to zero that the anticancer agent had a favourable risk/benefit profile,...
Please Login to read the full article.
RELATED CONTENT
NEWS
- FDA reviewers question efficacy of Pfizer's kidney cancer drug ahead of ODAC
- FDA gives thumbs up to Pfizer kidney cancer drug
- AVEO/Astellas 2012 filing for tivozanib as it beats Nexavar in Ph III kidney cancer trial
- EMA accepts Pfizer's axitinib for review in renal cell carcinoma
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
